Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.

Vast Therapeutics is celebrating the new year with Series A funding in excess of $15 million from Shionogi & Co., Ltd. (TYO: 4507) of Japan and a $300,000 award from the Cystic Fibrosis Foundation ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

While a cure remains elusive, several treatments exist to effectively manage the disease: CFTR Modulator ... mutations causing cystic fibrosis. Respiratory Therapies: These include airway clearance ...

This is the largest trial of its kind to evaluate PCT-guided antibiotic treatment in children but, despite promising previous analysis, the study found that using the PCT biomarker to guide ...

No single score captures the burden of treatment in people with cystic fibrosis (pwCF), according to systematic review study findings published in the Journal of Cystic Fibrosis. Researchers ...

A Nationwide Children's Hospital spinoff is developing a vaccine based on the same biotechnology it's testing as an antibody treatment ... cystic fibrosis, who are being treated with antibiotics ...

Casgevy and the company’s cystic fibrosis treatments, including standard-of-care Kaftrio and Trikafta, should help the drugmaker deliver 2025 revenues between $10.8 billion and $10.9 billion ...

In December, the FDA approved Vertex’s vanzacaftor, tezacaftor and deutivacaftor (Alyftrek) for the treatment of cystic fibrosis in ... is our fifth CFTR modulator to secure FDA approval and ...

Cystic fibrosis ... Advances in the treatment of common airway pathogens such as Pseudomonas aeruginosa have led to a marked improvement in overall survival. However, antibiotic treatment options ...

Ivacaftor Oral Granules, 25 mg, 50 mg and 75 mg per unit dose packet are indicated for cystic fibrosis treatment in patients aged 4 months and older. Mumbai: Global pharma major, Lupin Limited, has ...

“We also observed an initial decrease in ALT/AST in liver fibrosis patients treated with lixudebart.” Developed for the treatment of fibrosis in the liver, lungs and kidneys, lixudebart targets the ...